JP2017511376A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017511376A5 JP2017511376A5 JP2017501138A JP2017501138A JP2017511376A5 JP 2017511376 A5 JP2017511376 A5 JP 2017511376A5 JP 2017501138 A JP2017501138 A JP 2017501138A JP 2017501138 A JP2017501138 A JP 2017501138A JP 2017511376 A5 JP2017511376 A5 JP 2017511376A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- set forth
- sequence set
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 15
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 13
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 13
- 230000027455 binding Effects 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 108091034117 Oligonucleotide Proteins 0.000 claims description 7
- -1 anthracycline Natural products 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 239000003112 inhibitor Substances 0.000 claims description 5
- 230000004614 tumor growth Effects 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims description 4
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims description 4
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims description 3
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 3
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 2
- 230000000340 anti-metabolite Effects 0.000 claims description 2
- 229940100197 antimetabolite Drugs 0.000 claims description 2
- 239000002256 antimetabolite Substances 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 33
- 206010028980 Neoplasm Diseases 0.000 claims 14
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 14
- 239000000611 antibody drug conjugate Substances 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 239000000126 substance Substances 0.000 claims 5
- 238000003556 assay Methods 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 3
- 229940127121 immunoconjugate Drugs 0.000 claims 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 claims 2
- 102000001301 EGF receptor Human genes 0.000 claims 2
- 108060006698 EGF receptor Proteins 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 2
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims 2
- 108010044540 auristatin Proteins 0.000 claims 2
- 239000002872 contrast media Substances 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 238000002372 labelling Methods 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 108010093470 monomethyl auristatin E Proteins 0.000 claims 2
- 108010059074 monomethylauristatin F Proteins 0.000 claims 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- AXKGIPZJYUNAIW-UHFFFAOYSA-N (4-aminophenyl)methanol Chemical compound NC1=CC=C(CO)C=C1 AXKGIPZJYUNAIW-UHFFFAOYSA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 229940122035 Bcl-XL inhibitor Drugs 0.000 claims 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 108010092160 Dactinomycin Proteins 0.000 claims 1
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 1
- 229930183665 actinomycin Natural products 0.000 claims 1
- 229930013930 alkaloid Natural products 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000002424 anti-apoptotic effect Effects 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000013059 antihormonal agent Substances 0.000 claims 1
- 239000003972 antineoplastic antibiotic Substances 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 229910052796 boron Inorganic materials 0.000 claims 1
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 claims 1
- 229930195731 calicheamicin Natural products 0.000 claims 1
- 229960002173 citrulline Drugs 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 238000012875 competitive assay Methods 0.000 claims 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 claims 1
- 229930188854 dolastatin Natural products 0.000 claims 1
- 229960005501 duocarmycin Drugs 0.000 claims 1
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 claims 1
- 229930184221 duocarmycin Natural products 0.000 claims 1
- 230000008472 epithelial growth Effects 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 238000001215 fluorescent labelling Methods 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940116978 human epidermal growth factor Drugs 0.000 claims 1
- 229960001507 ibrutinib Drugs 0.000 claims 1
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 229910052738 indium Inorganic materials 0.000 claims 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 230000000394 mitotic effect Effects 0.000 claims 1
- 229960003966 nicotinamide Drugs 0.000 claims 1
- 235000005152 nicotinamide Nutrition 0.000 claims 1
- 239000011570 nicotinamide Substances 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 210000001236 prokaryotic cell Anatomy 0.000 claims 1
- 239000003223 protective agent Substances 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 229960004964 temozolomide Drugs 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 1
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 claims 1
- 229960001183 venetoclax Drugs 0.000 claims 1
- 150000001413 amino acids Chemical group 0.000 description 25
- 239000000427 antigen Substances 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 239000000074 antisense oligonucleotide Substances 0.000 description 7
- 238000012230 antisense oligonucleotides Methods 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 5
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 4
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 4
- 102000045108 human EGFR Human genes 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000003790 pyrimidine antagonist Substances 0.000 description 4
- HFEKDTCAMMOLQP-RRKCRQDMSA-N 5-fluorodeoxyuridine monophosphate Chemical compound O1[C@H](COP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C(F)=C1 HFEKDTCAMMOLQP-RRKCRQDMSA-N 0.000 description 3
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 3
- VPFUWHKTPYPNGT-UHFFFAOYSA-N 3-(3,4-dihydroxyphenyl)-1-(5-hydroxy-2,2-dimethylchromen-6-yl)propan-1-one Chemical compound OC1=C2C=CC(C)(C)OC2=CC=C1C(=O)CCC1=CC=C(O)C(O)=C1 VPFUWHKTPYPNGT-UHFFFAOYSA-N 0.000 description 2
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 2
- 108010066676 Abrin Proteins 0.000 description 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 2
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000016607 Diphtheria Toxin Human genes 0.000 description 2
- 108010053187 Diphtheria Toxin Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 101150039808 Egfr gene Proteins 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 101710183280 Topoisomerase Proteins 0.000 description 2
- 229960001467 bortezomib Drugs 0.000 description 2
- CTSPAMFJBXKSOY-UHFFFAOYSA-N ellipticine Chemical compound N1=CC=C2C(C)=C(NC=3C4=CC=CC=3)C4=C(C)C2=C1 CTSPAMFJBXKSOY-UHFFFAOYSA-N 0.000 description 2
- 108700021358 erbB-1 Genes Proteins 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 2
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 2
- YJGVMLPVUAXIQN-LGWHJFRWSA-N (5s,5ar,8ar,9r)-5-hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-LGWHJFRWSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- WVHGJJRMKGDTEC-WCIJHFMNSA-N 2-[(1R,4S,8R,10S,13S,16S,27R,34S)-34-[(2S)-butan-2-yl]-8,22-dihydroxy-13-[(2R,3S)-3-hydroxybutan-2-yl]-2,5,11,14,27,30,33,36,39-nonaoxo-27lambda4-thia-3,6,12,15,25,29,32,35,38-nonazapentacyclo[14.12.11.06,10.018,26.019,24]nonatriaconta-18(26),19(24),20,22-tetraen-4-yl]acetamide Chemical compound CC[C@H](C)[C@@H]1NC(=O)CNC(=O)[C@@H]2Cc3c([nH]c4cc(O)ccc34)[S@](=O)C[C@H](NC(=O)CNC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H]([C@@H](C)[C@H](C)O)C(=O)N2 WVHGJJRMKGDTEC-WCIJHFMNSA-N 0.000 description 1
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
- FBUTXZSKZCQABC-UHFFFAOYSA-N 2-amino-1-methyl-7h-purine-6-thione Chemical compound S=C1N(C)C(N)=NC2=C1NC=N2 FBUTXZSKZCQABC-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 101710092462 Alpha-hemolysin Proteins 0.000 description 1
- 101710197219 Alpha-toxin Proteins 0.000 description 1
- 231100000729 Amatoxin Toxicity 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 101000669426 Aspergillus restrictus Ribonuclease mitogillin Proteins 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 101710158575 Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase Proteins 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 101150015280 Cel gene Proteins 0.000 description 1
- 108700032819 Croton tiglium crotin II Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 101001055311 Equus asinus Immunoglobulin heavy constant alpha Proteins 0.000 description 1
- 101710082714 Exotoxin A Proteins 0.000 description 1
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 description 1
- 108700004714 Gelonium multiflorum GEL Proteins 0.000 description 1
- ZIXGXMMUKPLXBB-UHFFFAOYSA-N Guatambuinine Natural products N1C2=CC=CC=C2C2=C1C(C)=C1C=CN=C(C)C1=C2 ZIXGXMMUKPLXBB-UHFFFAOYSA-N 0.000 description 1
- 108010004889 Heat-Shock Proteins Chemical class 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 1
- 239000002118 L01XE12 - Vandetanib Substances 0.000 description 1
- 239000002145 L01XE14 - Bosutinib Substances 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 235000009811 Momordica charantia Nutrition 0.000 description 1
- 244000302512 Momordica charantia Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- SHGAZHPCJJPHSC-UHFFFAOYSA-N Panrexin Chemical compound OC(=O)C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-UHFFFAOYSA-N 0.000 description 1
- 101710124951 Phospholipase C Proteins 0.000 description 1
- 101100413173 Phytolacca americana PAP2 gene Proteins 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 241000882890 Renova Species 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- SUYXJDLXGFPMCQ-INIZCTEOSA-N SJ000287331 Natural products CC1=c2cnccc2=C(C)C2=Nc3ccccc3[C@H]12 SUYXJDLXGFPMCQ-INIZCTEOSA-N 0.000 description 1
- 108010084592 Saporins Proteins 0.000 description 1
- 108010055044 Tetanus Toxin Proteins 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229940064305 adrucil Drugs 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 239000002776 alpha toxin Substances 0.000 description 1
- 108010001818 alpha-sarcin Proteins 0.000 description 1
- 108010014709 amatoxin Proteins 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 229960003005 axitinib Drugs 0.000 description 1
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- 229960003736 bosutinib Drugs 0.000 description 1
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 description 1
- 229940088954 camptosar Drugs 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 190000008236 carboplatin Chemical compound 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 229960002412 cediranib Drugs 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229940099302 efudex Drugs 0.000 description 1
- 229940120655 eloxatin Drugs 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 description 1
- 229950005837 entinostat Drugs 0.000 description 1
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229940088013 hycamtin Drugs 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 229940100029 lysodren Drugs 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229960001346 nilotinib Drugs 0.000 description 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960005184 panobinostat Drugs 0.000 description 1
- FWZRWHZDXBDTFK-ZHACJKMWSA-N panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 description 1
- 108010076042 phenomycin Proteins 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000004713 phosphodiesters Chemical group 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 108010061338 ranpirnase Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009712 regulation of translation Effects 0.000 description 1
- 229940059527 renova Drugs 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 229940118376 tetanus toxin Drugs 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 229930013292 trichothecene Natural products 0.000 description 1
- 150000003327 trichothecene derivatives Chemical class 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 229960000241 vandetanib Drugs 0.000 description 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 1
- 229940099039 velcade Drugs 0.000 description 1
- 229940065658 vidaza Drugs 0.000 description 1
- 229960000237 vorinostat Drugs 0.000 description 1
- 229940053867 xeloda Drugs 0.000 description 1
- 229940061261 zolinza Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461968819P | 2014-03-21 | 2014-03-21 | |
| US61/968,819 | 2014-03-21 | ||
| PCT/US2015/021849 WO2015143382A1 (en) | 2014-03-21 | 2015-03-20 | Anti-egfr antibodies and antibody drug conjugates |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019212012A Division JP2020039360A (ja) | 2014-03-21 | 2019-11-25 | 抗ｅｇｆｒ抗体及び抗体薬物コンジュゲート |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017511376A JP2017511376A (ja) | 2017-04-20 |
| JP2017511376A5 true JP2017511376A5 (enExample) | 2018-06-28 |
Family
ID=52997522
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017501138A Ceased JP2017511376A (ja) | 2014-03-21 | 2015-03-20 | 抗ｅｇｆｒ抗体及び抗体薬物コンジュゲート |
| JP2019212012A Ceased JP2020039360A (ja) | 2014-03-21 | 2019-11-25 | 抗ｅｇｆｒ抗体及び抗体薬物コンジュゲート |
| JP2021052772A Ceased JP2021104030A (ja) | 2014-03-21 | 2021-03-26 | 抗ｅｇｆｒ抗体及び抗体薬物コンジュゲート |
| JP2023025869A Ceased JP2023062162A (ja) | 2014-03-21 | 2023-02-22 | 抗ｅｇｆｒ抗体及び抗体薬物コンジュゲート |
| JP2024074883A Ceased JP2024102229A (ja) | 2014-03-21 | 2024-05-02 | 抗ｅｇｆｒ抗体及び抗体薬物コンジュゲート |
| JP2025112297A Pending JP2025143392A (ja) | 2014-03-21 | 2025-07-02 | 抗ｅｇｆｒ抗体及び抗体薬物コンジュゲート |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019212012A Ceased JP2020039360A (ja) | 2014-03-21 | 2019-11-25 | 抗ｅｇｆｒ抗体及び抗体薬物コンジュゲート |
| JP2021052772A Ceased JP2021104030A (ja) | 2014-03-21 | 2021-03-26 | 抗ｅｇｆｒ抗体及び抗体薬物コンジュゲート |
| JP2023025869A Ceased JP2023062162A (ja) | 2014-03-21 | 2023-02-22 | 抗ｅｇｆｒ抗体及び抗体薬物コンジュゲート |
| JP2024074883A Ceased JP2024102229A (ja) | 2014-03-21 | 2024-05-02 | 抗ｅｇｆｒ抗体及び抗体薬物コンジュゲート |
| JP2025112297A Pending JP2025143392A (ja) | 2014-03-21 | 2025-07-02 | 抗ｅｇｆｒ抗体及び抗体薬物コンジュゲート |
Country Status (22)
| Country | Link |
|---|---|
| US (7) | US9493568B2 (enExample) |
| EP (2) | EP3126006A1 (enExample) |
| JP (6) | JP2017511376A (enExample) |
| KR (3) | KR20220025946A (enExample) |
| CN (5) | CN110845616A (enExample) |
| AR (2) | AR099812A1 (enExample) |
| AU (4) | AU2015231001A1 (enExample) |
| CA (1) | CA2942101A1 (enExample) |
| CL (3) | CL2016002359A1 (enExample) |
| CR (2) | CR20210097A (enExample) |
| DO (2) | DOP2016000252A (enExample) |
| EC (1) | ECSP16082556A (enExample) |
| IL (2) | IL295906A (enExample) |
| MX (2) | MX385853B (enExample) |
| PE (2) | PE20211798A1 (enExample) |
| PH (2) | PH12021552141A1 (enExample) |
| RU (2) | RU2016141267A (enExample) |
| SG (3) | SG10201808837RA (enExample) |
| TW (5) | TWI684600B (enExample) |
| UA (1) | UA125575C2 (enExample) |
| UY (1) | UY36041A (enExample) |
| WO (1) | WO2015143382A1 (enExample) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX358640B (es) | 2008-01-04 | 2018-08-29 | Intellikine Llc | Isoquinolin-1 (2h) -onas y tieno [2,3-d]pirimidin-4(3h) -onas substituidas, y metodos de uso de las mismas. |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| TWI546305B (zh) | 2011-01-10 | 2016-08-21 | 英菲尼提製藥股份有限公司 | 製備異喹啉酮之方法及異喹啉酮之固體形式 |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| CN105102000B (zh) | 2012-11-01 | 2021-10-22 | 无限药品公司 | 使用pi3激酶亚型调节剂的癌症疗法 |
| PL2970378T3 (pl) | 2013-03-15 | 2021-12-06 | Biogen Ma Inc. | Chromatografia oddziaływań hydrofobowych białek w warunkach bez soli |
| CN110845616A (zh) | 2014-03-21 | 2020-02-28 | 艾伯维公司 | 抗-egfr抗体及抗体药物偶联物 |
| WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| WO2015172339A1 (zh) * | 2014-05-14 | 2015-11-19 | 科济生物医药（上海）有限公司 | 编码嵌合抗原受体蛋白的核酸及表达嵌合抗原受体蛋白的t淋巴细胞 |
| CA2944085C (en) * | 2014-09-16 | 2018-04-10 | Ease Charm Limited | Anti-egfr antibody and uses of same |
| TWI787796B (zh) | 2015-05-04 | 2022-12-21 | 美商Ｃｙｔｏｍｘ生物製藥公司 | 抗ｃｄ７１抗體類、可活化之抗ｃｄ７１抗體類及使用彼等之方法 |
| KR101776238B1 (ko) * | 2015-06-12 | 2017-09-12 | 사회복지법인 삼성생명공익재단 | 교모세포종 환자에서 이브루티닙 감수성과 관련된 유전자 및 그 용도 |
| CN107922477B (zh) * | 2015-06-29 | 2022-11-01 | 第一三共株式会社 | 用于选择性制造抗体-药物缀合物的方法 |
| US11583593B2 (en) | 2016-01-14 | 2023-02-21 | Synthis Therapeutics, Inc. | Antibody-ALK5 inhibitor conjugates and their uses |
| EP3368056B1 (en) * | 2016-01-26 | 2025-08-20 | Raghoottama Pandurangi | Compositions and methods for sensitizing low responsive tumors to cancer therapy |
| BR112018014467A2 (en) * | 2016-02-04 | 2018-12-11 | Ni Jinsong | drug-antibody synergism technology for disease treatment |
| AU2017277422A1 (en) | 2016-06-08 | 2019-01-03 | Abbvie Inc. | Anti-EGFR antibody drug conjugates |
| JP2019521106A (ja) * | 2016-06-08 | 2019-07-25 | アッヴィ・インコーポレイテッド | 抗ｅｇｆｒ抗体薬物コンジュゲート |
| PL3458479T4 (pl) | 2016-06-08 | 2021-07-26 | Abbvie Inc. | Przeciwciała anty-b7-h3 i koniugaty przeciwciało-lek |
| JP2019521975A (ja) * | 2016-06-08 | 2019-08-08 | アッヴィ・インコーポレイテッド | 抗ｅｇｆｒ抗体薬物コンジュゲート |
| CN107522785B (zh) * | 2016-06-22 | 2020-05-08 | 北京大学 | 抗egfr突变体iii单克隆抗体、制备方法及其应用 |
| EP3474856B1 (en) | 2016-06-24 | 2022-09-14 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| CN108472371B (zh) * | 2016-07-05 | 2022-05-24 | 江苏恒瑞医药股份有限公司 | Egfr抗体-药物偶联物及其在医药上的应用 |
| ES2837755T3 (es) | 2016-09-14 | 2021-07-01 | Abbvie Biotherapeutics Inc | Anticuerpos anti-PD-1 |
| WO2018112027A1 (en) * | 2016-12-14 | 2018-06-21 | Development Center For Biotechnology | Antibody-drug conjugates and uses thereof |
| EP3645041A4 (en) | 2017-06-28 | 2021-03-17 | The Rockefeller University | AGONISTIC ANTIBODY-ANTIBODY-ACTIVE INGREDIENT CONJUGATES AGAINST MERTK AND THEIR USES |
| CA3070297A1 (en) * | 2017-08-11 | 2019-02-14 | Genentech, Inc. | Anti-cd8 antibodies and uses thereof |
| SG11202001762RA (en) * | 2017-09-02 | 2020-03-30 | Abbvie Inc | Anti-egfr antibody drug conjugates (adc) and uses thereof |
| JP2020532543A (ja) * | 2017-09-02 | 2020-11-12 | アッヴィ・インコーポレイテッド | 抗ｅｇｆｒ抗体薬物コンジュゲート（ａｄｃ）及びその使用 |
| CA3081925A1 (en) | 2017-11-18 | 2019-05-23 | Nzola DE MAGALHAES | Product and process for employing gc7 (n1-guanyl-1,7-diaminoheptane) based antigen binding conjugates in cancer therapy |
| EP3753952A4 (en) * | 2017-12-13 | 2022-04-13 | XDCExplorer (Shanghai) Co., Ltd. | EGFRVIII ANTIBODY AND CONJUGATE, AND METHODS FOR ITS PRODUCTION AND USE |
| WO2019114793A1 (zh) * | 2017-12-13 | 2019-06-20 | 凯惠科技发展(上海)有限公司 | 一种egfr抗体及其制备方法和应用 |
| EA202091672A1 (ru) * | 2018-01-08 | 2021-02-01 | Регенерон Фармасьютикалз, Инк. | Стероиды и их антитело-конъюгаты |
| WO2019149637A1 (en) * | 2018-01-31 | 2019-08-08 | Bayer Aktiengesellschaft | Antibody drug conjugates (adcs) with nampt inhibitors |
| SG11202007622SA (en) * | 2018-02-11 | 2020-09-29 | Memorial Sloan Kettering Cancer Center | Non-hla restricted t cell receptors and uses thereof |
| IL277095B2 (en) * | 2018-03-07 | 2025-10-01 | Pfizer | Preparations containing anti-PD-1 antibody |
| WO2019195586A1 (en) | 2018-04-06 | 2019-10-10 | The Regents Of The University Of California | Methods of treating egfrviii expressing glioblastomas |
| US12090170B2 (en) | 2018-04-06 | 2024-09-17 | The Regents Of The University Of California | Methods of treating glioblastomas |
| AR114789A1 (es) * | 2018-04-18 | 2020-10-14 | Hoffmann La Roche | Anticuerpos anti-hla-g y uso de los mismos |
| WO2019211708A1 (en) * | 2018-05-04 | 2019-11-07 | Kashiv Biosciences, Llc | Stable pharmaceutical compositions of dianhydrogalactitol |
| WO2019227490A1 (en) | 2018-06-01 | 2019-12-05 | Tayu Huaxia Biotech Medical Group Co., Ltd. | Compositions and methods for imaging |
| WO2019228514A1 (en) | 2018-06-01 | 2019-12-05 | Tayu Huaxia Biotech Medical Group Co., Ltd. | Compositions and uses thereof for treating disease or condition |
| BR112021000620A2 (pt) | 2018-07-15 | 2021-04-20 | Enochian BioPharma, Inc. | métodos e composições com uso de células dendríticas recombinantes para terapia contra câncer |
| US20210309745A1 (en) * | 2018-07-26 | 2021-10-07 | Tayu Huaxia Biotech Medical Group Co., Ltd. | Compositions and methods for imaging |
| CA3112043A1 (en) | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
| CN109200291B (zh) * | 2018-10-24 | 2021-06-08 | 中国医学科学院医药生物技术研究所 | 一种靶向于egfr的抗体偶联药物及其制备方法和其用途 |
| WO2020151572A1 (en) | 2019-01-23 | 2020-07-30 | Tayu Huaxia Biotech Medical Group Co., Ltd. | Anti-pd-l1 diabodies and the use thereof |
| US12109273B2 (en) | 2019-02-15 | 2024-10-08 | Wuxi Xdc Singapore Private Limited | Process for preparing antibody-drug conjugates with improved homogeneity |
| TWI756633B (zh) * | 2019-02-15 | 2022-03-01 | 大陸商上海藥明生物技術有限公司 | 具有改善的同質性的抗體－藥物綴合物、其藥物組合物、用途和製備方法 |
| US20220184129A1 (en) * | 2019-04-12 | 2022-06-16 | The Trustees Of The University Of Pennsylvania | Compositions and Methods Comprising a High Affinity Chimeric Antigen Receptor (CAR) with Cross-Reactivity to Clinically-Relevant EGFR Mutated Proteins |
| WO2020256721A1 (en) * | 2019-06-19 | 2020-12-24 | Synthis, Llc | Antib0dy-alk5 inhibitor conjugates and their uses |
| CN110845623B (zh) * | 2019-10-11 | 2021-07-09 | 厦门大学 | 一种egfr特异性嵌合抗原受体及其应用 |
| WO2021135178A1 (zh) * | 2019-12-30 | 2021-07-08 | 华夏英泰（北京）生物技术有限公司 | 一种增强型t细胞受体star及其应用 |
| KR20230003114A (ko) * | 2020-04-28 | 2023-01-05 | 사이노셀테크 엘티디. | TGFβR2 세포외 도메인 절단된 분자, TGFβR2 세포외 도메인 절단된 분자와 항-EGFR 항체의 융합 단백질, 및 융합 단백질의 항종양 용도 |
| AU2020454676A1 (en) * | 2020-06-24 | 2023-02-23 | Sapreme Technologies B.V. | Conjugate of a single domain antibody, a saponin and an effector molecule, pharmaceutical composition comprising the same, therapeutic use of said pharmaceutical composition |
| EP4117730A1 (en) * | 2020-06-24 | 2023-01-18 | Sapreme Technologies B.V. | Conjugate of saponin and single-domain antibody, pharmaceutical composition comprising said conjugate, therapeutic use thereof |
| AU2021320253A1 (en) | 2020-08-05 | 2023-03-02 | Dragonfly Therapeutics, Inc. | Antibodies targeting EGFR and use thereof |
| US20240307539A1 (en) | 2020-09-30 | 2024-09-19 | Institute Of Zoology, Chinese Academy Of Science | Egfr-targeting chimeric antigen receptor |
| CN112442355B (zh) * | 2020-11-28 | 2022-04-05 | 江西师范大学 | 一种稀土-透明质酸配位聚合物包覆的vs2纳米结构及其制备方法和应用 |
| EP4263600A1 (en) | 2020-12-18 | 2023-10-25 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| AR124681A1 (es) | 2021-01-20 | 2023-04-26 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
| WO2022240757A1 (en) | 2021-05-10 | 2022-11-17 | Entrada Therapeutics, Inc. | Antigen-binding and antigen degradation constructs |
| CN114044826B (zh) * | 2021-10-12 | 2023-11-17 | 南京融捷康生物科技有限公司 | 针对EGFRvIII的单域抗体及其衍生蛋白和应用 |
| US20230220106A1 (en) | 2021-12-08 | 2023-07-13 | Dragonfly Therapeutics, Inc. | Antibodies targeting 5t4 and uses thereof |
| TW202434307A (zh) | 2023-01-18 | 2024-09-01 | 大陸商泰勵生物科技（上海）有限公司 | 抗體偶聯藥物及其用途 |
| CN117659203B (zh) * | 2023-12-06 | 2024-08-13 | 科弈(浙江)药业科技有限公司 | 一种抗met/egfr双特异性抗体及其药物偶联物 |
Family Cites Families (180)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US938A (en) | 1838-09-22 | Improvement in paddle-wheels for propelling boats | ||
| US4526A (en) | 1846-05-16 | Improvement in the mode o | ||
| US8236A (en) | 1851-07-22 | Hanging cakriage-body | ||
| US319A (en) | 1837-07-31 | Improvement in machines for breaking and dressing hemp and flax | ||
| US4434150A (en) | 1981-10-19 | 1984-02-28 | Ortho Diagnostic Systems, Inc. | Immunological reagents employing polymeric backbone possessing reactive functional groups |
| US4486414A (en) | 1983-03-21 | 1984-12-04 | Arizona Board Of Reagents | Dolastatins A and B cell growth inhibitory substances |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| US5128326A (en) | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
| FR2601675B1 (fr) | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US4880078A (en) | 1987-06-29 | 1989-11-14 | Honda Giken Kogyo Kabushiki Kaisha | Exhaust muffler |
| US4816444A (en) | 1987-07-10 | 1989-03-28 | Arizona Board Of Regents, Arizona State University | Cell growth inhibitory substance |
| US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
| US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
| IL106992A (en) | 1988-02-11 | 1994-06-24 | Bristol Myers Squibb Co | Acylhydrazone derivatives of anthracycline and methods for their preparation |
| US5157049A (en) | 1988-03-07 | 1992-10-20 | The United States Of America As Represented By The Department Of Health & Human Services | Method of treating cancers sensitive to treatment with water soluble derivatives of taxol |
| US4942184A (en) | 1988-03-07 | 1990-07-17 | The United States Of America As Represented By The Department Of Health And Human Services | Water soluble, antineoplastic derivatives of taxol |
| US5076973A (en) | 1988-10-24 | 1991-12-31 | Arizona Board Of Regents | Synthesis of dolastatin 3 |
| WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| US4978744A (en) | 1989-01-27 | 1990-12-18 | Arizona Board Of Regents | Synthesis of dolastatin 10 |
| US4960790A (en) | 1989-03-09 | 1990-10-02 | University Of Kansas | Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof |
| US4879278A (en) | 1989-05-16 | 1989-11-07 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15 |
| US4986988A (en) | 1989-05-18 | 1991-01-22 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13 |
| ATE135373T1 (de) | 1989-09-08 | 1996-03-15 | Univ Johns Hopkins | Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma |
| WO1991005548A1 (en) | 1989-10-10 | 1991-05-02 | Pitman-Moore, Inc. | Sustained release composition for macromolecular proteins |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| AU642932B2 (en) | 1989-11-06 | 1993-11-04 | Alkermes Controlled Therapeutics, Inc. | Protein microspheres and methods of using them |
| US5138036A (en) | 1989-11-13 | 1992-08-11 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14 |
| US5124471A (en) | 1990-03-26 | 1992-06-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Bifunctional dtpa-type ligand |
| AU7774391A (en) | 1990-04-20 | 1991-11-11 | Ludwig Institute For Cancer Research | Aberrant, epidermal growth factor receptor dna, rna and protein forms and method |
| US5407683A (en) | 1990-06-01 | 1995-04-18 | Research Corporation Technologies, Inc. | Pharmaceutical solutions and emulsions containing taxol |
| US5278324A (en) | 1990-08-28 | 1994-01-11 | Virginia Tech Intellectual Properties, Inc. | Water soluble derivatives of taxol |
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| US5795965A (en) | 1991-04-25 | 1998-08-18 | Chugai Seiyaku Kabushiki Kaisha | Reshaped human to human interleukin-6 receptor |
| JPH06507404A (ja) | 1991-05-01 | 1994-08-25 | ヘンリー エム．ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン | 感染性の呼吸性疾患の治療方法 |
| US6287792B1 (en) | 1991-06-17 | 2001-09-11 | The Regents Of The University Of California | Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology |
| FR2678833B1 (fr) | 1991-07-08 | 1995-04-07 | Rhone Poulenc Rorer Sa | Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes. |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
| ATE194767T1 (de) | 1992-03-23 | 2000-08-15 | Univ Georgetown | In liposomen verkapseltes taxol und verwendungsverfahren |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| GB9213077D0 (en) | 1992-06-19 | 1992-08-05 | Erba Carlo Spa | Polymerbound taxol derivatives |
| CA2086874E (en) | 1992-08-03 | 2000-01-04 | Renzo Mauro Canetta | Methods for administration of taxol |
| FR2696458B1 (fr) | 1992-10-05 | 1994-11-10 | Rhone Poulenc Rorer Sa | Procédé de préparation de dérivés du taxane. |
| FR2697752B1 (fr) | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Compositions antitumorales contenant des dérivés du taxane. |
| FR2698543B1 (fr) | 1992-12-02 | 1994-12-30 | Rhone Poulenc Rorer Sa | Nouvelles compositions à base de taxoides. |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US6034065A (en) | 1992-12-03 | 2000-03-07 | Arizona Board Of Regents | Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10 |
| US5380751A (en) | 1992-12-04 | 1995-01-10 | Bristol-Myers Squibb Company | 6,7-modified paclitaxels |
| US5410024A (en) | 1993-01-21 | 1995-04-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| WO1994016729A1 (en) | 1993-01-28 | 1994-08-04 | Neorx Corporation | Targeted nitric oxide pathway or nitric oxide synthase modulation |
| US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
| US5433364A (en) | 1993-02-19 | 1995-07-18 | Dynetics Engineering Corporation | Card package production system with burster and carrier verification apparatus |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US5415869A (en) | 1993-11-12 | 1995-05-16 | The Research Foundation Of State University Of New York | Taxol formulation |
| WO1995015770A1 (en) | 1993-12-09 | 1995-06-15 | Neorx Corporation | Pretargeting methods and compounds |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| IT1275043B (it) | 1994-07-21 | 1997-07-29 | Agerbioss Snc Di Zanin R & C | Metodo e relativo prodotto per la difesa delle piante dai parassiti vegetali |
| US5504191A (en) | 1994-08-01 | 1996-04-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide methyl esters |
| US5530097A (en) | 1994-08-01 | 1996-06-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory peptide amides |
| US5521284A (en) | 1994-08-01 | 1996-05-28 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides and esters |
| US5554725A (en) | 1994-09-14 | 1996-09-10 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Synthesis of dolastatin 15 |
| US5599902A (en) | 1994-11-10 | 1997-02-04 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Cancer inhibitory peptides |
| DE69532767T2 (de) | 1994-11-28 | 2004-08-12 | Thomas Jefferson University | Peptid umfassend eine Sequenz aus einer Fusionsverbindungsstelle in einem mutierten EGF-Rezeptor vom Typ III |
| US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
| EP0805678B1 (en) | 1995-01-05 | 2003-10-29 | THE BOARD OF REGENTS acting for and on behalf of THE UNIVERSITY OF MICHIGAN | Surface-modified nanoparticles and method of making and using same |
| US5840929A (en) | 1995-04-14 | 1998-11-24 | Bristol-Myers Squibb Company | C4 methoxy ether derivatives of paclitaxel |
| US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| US5705503A (en) | 1995-05-25 | 1998-01-06 | Goodall; Brian Leslie | Addition polymers of polycycloolefins containing functional substituents |
| US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US6127977A (en) | 1996-11-08 | 2000-10-03 | Cohen; Nathan | Microstrip patch antenna with fractal structure |
| AU710347B2 (en) | 1995-08-31 | 1999-09-16 | Alkermes Controlled Therapeutics, Inc. | Composition for sustained release of an agent |
| US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| DK0871490T3 (da) | 1995-12-22 | 2003-07-07 | Bristol Myers Squibb Co | Forgrenede hydrazonlinkere |
| DE69721548T2 (de) | 1996-02-09 | 2004-04-01 | Abbott Laboratories(Bermuda)Ltd. | HUMANE ANTIKÖRPER WELCHE AN HUMANEN TNFalpha BINDEN |
| IT1282692B1 (it) | 1996-02-27 | 1998-03-31 | San Raffaele Centro Fond | Citochine modificate per l'uso in terapia |
| ATE508733T1 (de) | 1996-03-04 | 2011-05-15 | Penn State Res Found | Materialien und verfahren zur steigerung der zellulären internalisierung |
| US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US5821263A (en) | 1996-08-26 | 1998-10-13 | Bristol-Myers Squibb Company | Sulfenamide taxane derivatives |
| US5773464A (en) | 1996-09-30 | 1998-06-30 | Bristol-Myers Squibb Company | C-10 epoxy taxanes |
| AU4966597A (en) | 1996-11-19 | 1998-06-10 | Daiichi Pharmaceutical Co., Ltd. | Taxol derivatives |
| US5977386A (en) | 1996-12-24 | 1999-11-02 | Bristol-Myers Squibb Company | 6-thio-substituted paclitaxels |
| WO1998031346A1 (en) | 1997-01-16 | 1998-07-23 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| AU750451B2 (en) | 1997-02-13 | 2002-07-18 | Bone Care International, Inc. | Targeted therapeutic delivery of vitamin D compounds |
| DE69832158T2 (de) | 1997-02-25 | 2006-08-10 | Arizona Board Of Regents, Tempe | Isolierung und strukturelle aufklärung der kryostatischen linearen und cyclo-depsipeptide dolastatin 16, dolastatin 17, und dolastatin 18 |
| US7288665B1 (en) | 1997-08-18 | 2007-10-30 | Florida State University | Process for selective derivatization of taxanes |
| JPH1192468A (ja) | 1997-09-17 | 1999-04-06 | Yakult Honsha Co Ltd | 新規なタキサン誘導体 |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| DE69729128T2 (de) | 1997-10-08 | 2005-04-28 | Bio Research Corporation Of Yokohama, Yokohama | Taxoid-derivate und verfahren zu ihrer herstellung |
| AU9692498A (en) | 1997-10-10 | 1999-05-03 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Complex of biotinylated viral vector and ligand for targeted gene delivery |
| SE512663C2 (sv) | 1997-10-23 | 2000-04-17 | Biogram Ab | Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer |
| CA2336139C (en) | 1998-06-24 | 2008-10-14 | Advanced Inhalation Research, Inc. | Large porous particles emitted from an inhaler |
| AU2472400A (en) | 1998-10-20 | 2000-05-08 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| CA2369292C (en) | 1999-04-09 | 2010-09-21 | Kyowa Hakko Kogyo Co. Ltd. | Method of modulating the activity of functional immune molecules |
| CN1269087C (zh) | 1999-07-31 | 2006-08-09 | 朴奎珍 | 使用数字音频和字幕数据的学习方法和装置 |
| US6323315B1 (en) | 1999-09-10 | 2001-11-27 | Basf Aktiengesellschaft | Dolastatin peptides |
| AU2001271273A1 (en) | 2000-05-24 | 2001-12-03 | Ludwig Institute For Cancer Research | Multicomponent conjugates which bind to target molecules and stimulate cell lysis |
| US7449308B2 (en) | 2000-06-28 | 2008-11-11 | Glycofi, Inc. | Combinatorial DNA library for producing modified N-glycans in lower eukaryotes |
| KR100787073B1 (ko) | 2000-06-28 | 2007-12-21 | 글리코파이, 인크. | 변형된 당단백질의 제조방법 |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US20030083263A1 (en) | 2001-04-30 | 2003-05-01 | Svetlana Doronina | Pentapeptide compounds and uses related thereto |
| PT1392359E (pt) | 2001-05-11 | 2010-01-27 | Ludwig Inst For Cancer Res Ltd | Proteínas de ligação específica e suas utilizações |
| US20110313230A1 (en) | 2001-05-11 | 2011-12-22 | Terrance Grant Johns | Specific binding proteins and uses thereof |
| US20100056762A1 (en) * | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| US20040192898A1 (en) | 2001-08-17 | 2004-09-30 | Jia Audrey Yunhua | Anti-abeta antibodies |
| ATE430580T1 (de) | 2001-10-25 | 2009-05-15 | Genentech Inc | Glycoprotein-zusammensetzungen |
| US20040028687A1 (en) | 2002-01-15 | 2004-02-12 | Waelti Ernst Rudolf | Methods and compositions for the targeted delivery of therapeutic substances to specific cells and tissues |
| AU2003234327B2 (en) | 2002-05-01 | 2008-05-29 | Trellis Bioscience, Inc. | Binary or polynary targeting and uses thereof |
| US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| CA2802205C (en) | 2002-07-31 | 2016-01-19 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
| JP2006500364A (ja) | 2002-08-16 | 2006-01-05 | イムノージェン インコーポレーテッド | 高い反応性と溶解度を有する架橋剤および小分子薬物の標的化送達用コンジュゲートの調製におけるそれらの使用 |
| US7388079B2 (en) | 2002-11-27 | 2008-06-17 | The Regents Of The University Of California | Delivery of pharmaceutical agents via the human insulin receptor |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| CA2517145C (en) | 2003-03-05 | 2017-08-01 | Halozyme, Inc. | Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| KR101531400B1 (ko) * | 2003-06-27 | 2015-06-26 | 암젠 프레몬트 인코포레이티드 | 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그용도 |
| AU2004280333A1 (en) | 2003-08-22 | 2005-04-21 | Medimmune, Llc | Humanization of antibodies |
| NZ583292A (en) | 2003-11-06 | 2012-03-30 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
| US7767792B2 (en) | 2004-02-20 | 2010-08-03 | Ludwig Institute For Cancer Research Ltd. | Antibodies to EGF receptor epitope peptides |
| US7906624B2 (en) | 2004-02-20 | 2011-03-15 | The Trustees Of The University Of Pennsylvania | Binding peptidomimetics and uses of the same |
| CA2558195C (en) | 2004-03-01 | 2012-11-06 | Spirogen Limited | 11-hydroxy-5h-pyrrolo[2,1-c][1,4]benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepines |
| US20050226882A1 (en) | 2004-04-08 | 2005-10-13 | Awdalla Essam T | Method and multicomponent conjugates for treating cancer |
| AU2005233387B2 (en) | 2004-04-15 | 2011-05-26 | Glycofi, Inc. | Production of galactosylated glycoproteins in lower eukaryotes |
| RU2402548C2 (ru) | 2004-05-19 | 2010-10-27 | Медарекс, Инк. | Химические линкеры и их конъюгаты |
| MXPA06014065A (es) | 2004-06-01 | 2007-01-31 | Genentech Inc | Conjugados de droga-anticuerpo y metodos. |
| WO2006042146A2 (en) | 2004-10-07 | 2006-04-20 | Emory University | Multifunctional nanoparticles conjugates and their use |
| US7263946B2 (en) | 2004-11-01 | 2007-09-04 | Craig Worthy | System for measuring chain or rope deployment |
| EP1695717A1 (en) | 2005-02-23 | 2006-08-30 | Ludwig-Maximilians-Universität | Transport of nano-and macromolecular structures into cytoplasm and nucleus of cells |
| AU2006238686B2 (en) | 2005-04-21 | 2011-10-06 | Medimmune Limited | Pyrrolobenzodiazepines |
| US7447597B2 (en) | 2005-05-06 | 2008-11-04 | Exxonmobil Research And Engineering Company | Data processing/visualization method for two (multi) dimensional separation gas chromatography xmass spectrometry (GCxMS) technique with a two (multiply) dimensional separation concept as an example |
| PT3248613T (pt) | 2005-07-18 | 2022-03-16 | Seagen Inc | Conjugados de ligante de fármaco e beta-glucuronida |
| EP2041175A4 (en) | 2006-06-23 | 2011-03-16 | Augmenta Biolog Llc | TARGETED IMMUNOJUGATE |
| EP2068929A4 (en) | 2006-09-15 | 2010-04-28 | Life Science Pharmaceuticals | METHOD OF DETECTING AND TREATING SKIN DISORDERS |
| US7598028B2 (en) | 2006-11-28 | 2009-10-06 | The Regents Of The University Of Michigan | Compositions and methods for detecting and treating prostate disorders |
| WO2008091701A2 (en) * | 2007-01-25 | 2008-07-31 | Dana-Farber Cancer Institute | Use of anti-egfr antibodies in treatment of egfr mutant mediated disease |
| TWI422594B (zh) | 2007-02-02 | 2014-01-11 | Baylor Res Inst | 經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑 |
| BRPI0807160A2 (pt) | 2007-02-02 | 2018-09-25 | Baylor Res Institute | vacinas baseadas no direcionamento de antígeno ao dcir expresso em células apresentadoras de antígeno |
| HRP20131113T1 (hr) | 2007-02-16 | 2014-01-17 | Merrimack Pharmaceuticals, Inc. | Protutijela protiv erbb3 i njihova uporaba |
| EP2132226B1 (en) | 2007-02-23 | 2019-03-27 | Baylor Research Institute | Activation of human antigen-presenting cells through dendritic cell lectin-like oxidized ldl receptor-1 (lox-1) |
| CA2717656A1 (en) | 2007-02-23 | 2008-08-28 | Baylor Research Institute | Activation of human antigen-presenting cells through clec-6 |
| CA2680854C (en) | 2007-03-15 | 2017-02-14 | Ludwig Institute For Cancer Research | Treatment method using egfr antibodies and src inhibitors and related formulations |
| JP5394246B2 (ja) * | 2007-03-30 | 2014-01-22 | ジェネンテック， インコーポレイテッド | 抗体及びイムノコンジュゲートとこれらの使用方法 |
| PT2856876T (pt) | 2007-03-30 | 2018-03-28 | Memorial Sloan Kettering Cancer Center | Expressão constitutiva de ligantes co-estimulatórios em linfócitos t adotivamente transferidos |
| EP1985633A1 (en) * | 2007-04-26 | 2008-10-29 | LFB Biotechnologies | Kit of parts for the treatment of cancer or infectious diseases |
| EP2208737B1 (en) | 2007-05-03 | 2017-07-05 | Lysomab GmbH | Complement factor H-derived short consensus repeat-antibody constructs |
| MX2010001757A (es) | 2007-08-14 | 2010-09-14 | Ludwig Inst Cancer Res | Anticuerpo monoclonal 175 que activa el receptor egf y derivados y usos del mismo. |
| EP2240581B1 (en) | 2008-01-15 | 2016-05-11 | AbbVie Inc. | Improved mammalian expression vectors and uses thereof |
| FR2931243A1 (fr) | 2008-05-14 | 2009-11-20 | Inst Francais Du Petrole | Procede pour determiner des proprietes physico-chimiques d'un echantillon petrolier a partir de chromatographie en phase gazeuse bidimensionnelle |
| US20090285757A1 (en) | 2008-05-16 | 2009-11-19 | Northeastern University | Methods of targeting cells for diagnosis and therapy |
| PL3006459T3 (pl) | 2008-08-26 | 2022-01-17 | City Of Hope | Sposób i kompozycje dla wzmocnionego działania efektorowego komórek t przeciw guzowi nowotworowemu |
| AU2010229192A1 (en) | 2009-03-06 | 2011-09-29 | Agensys, Inc. | Antibody drug conjugates (ADC) that bind to 24P4C12 proteins |
| CN104861066B (zh) | 2009-03-23 | 2018-05-08 | 夸克制药公司 | 治疗癌症和纤维化疾病的化合物组合物和方法 |
| DE102009026075A1 (de) | 2009-06-30 | 2011-01-05 | Röhm Gmbh | Bohrvorrichtung |
| US20110076232A1 (en) | 2009-09-29 | 2011-03-31 | Ludwig Institute For Cancer Research | Specific binding proteins and uses thereof |
| WO2011057216A1 (en) | 2009-11-06 | 2011-05-12 | The Pennsylvania State Research Foundation | Bioconjugation of calcium phosphosilicate nanoparticles for selective targeting of cells in vivo |
| GB0919751D0 (en) | 2009-11-11 | 2009-12-30 | King S College Hospital Nhs Fo | Conjugate molecule |
| US20110217363A1 (en) | 2010-03-05 | 2011-09-08 | Bionanox | Two-step targeted tumor therapy with prodrug encapsulated in nanocarrier |
| NZ602932A (en) | 2010-04-15 | 2014-08-29 | Seattle Genetics Inc | Targeted pyrrolobenzodiazapine conjugates |
| US20110256157A1 (en) | 2010-04-15 | 2011-10-20 | Spirogen Limited | Pyrrolobenzodiazepines and conjugates thereof |
| SMT201700547T1 (it) * | 2010-06-15 | 2018-01-11 | Genmab As | Coniugati di farmaco anticorpo umano contro il fattore tissutale |
| WO2012027494A1 (en) | 2010-08-24 | 2012-03-01 | Regents Of The University Of Minnesota | Bispecific targeting reagents |
| US8637642B2 (en) * | 2010-09-29 | 2014-01-28 | Seattle Genetics, Inc. | Antibody drug conjugates (ADC) that bind to 191P4D12 proteins |
| AU2011320314B2 (en) * | 2010-10-29 | 2015-08-06 | Immunogen, Inc. | Novel EGFR-binding molecules and immunoconjugates thereof |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| SG11201402343SA (en) * | 2011-11-21 | 2014-06-27 | Immunogen Inc | Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate |
| JP2015520752A (ja) | 2012-05-11 | 2015-07-23 | アッヴィ・インコーポレイテッド | Ｎａｍｐｔ阻害薬としてのピリダジンおよびピリジン誘導体 |
| SG11201505896YA (en) | 2013-02-20 | 2015-09-29 | Novartis Ag | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor |
| EP2968552B1 (en) * | 2013-03-14 | 2020-03-11 | The Scripps Research Institute | Targeting agent antibody conjugates and uses thereof |
| HRP20190672T1 (hr) | 2013-03-15 | 2019-08-23 | AbbVie Deutschland GmbH & Co. KG | Konjugirane formulacije anti-egfr protutijelo-lijek |
| WO2014152199A1 (en) | 2013-03-15 | 2014-09-25 | Abbvie Inc. | Antibody drug conjugate (adc) purification |
| KR102357968B1 (ko) | 2013-10-15 | 2022-02-03 | 더 스크립스 리서치 인스티튜트 | 키메라 항원 수용체 t 세포 스위치 및 이의 용도 |
| CN110845616A (zh) | 2014-03-21 | 2020-02-28 | 艾伯维公司 | 抗-egfr抗体及抗体药物偶联物 |
-
2015
- 2015-03-20 CN CN201911118205.9A patent/CN110845616A/zh active Pending
- 2015-03-20 CR CR20210097A patent/CR20210097A/es unknown
- 2015-03-20 KR KR1020227005625A patent/KR20220025946A/ko not_active Withdrawn
- 2015-03-20 SG SG10201808837RA patent/SG10201808837RA/en unknown
- 2015-03-20 EP EP15718003.5A patent/EP3126006A1/en not_active Withdrawn
- 2015-03-20 PE PE2021000787A patent/PE20211798A1/es unknown
- 2015-03-20 CA CA2942101A patent/CA2942101A1/en active Pending
- 2015-03-20 PH PH1/2021/552141A patent/PH12021552141A1/en unknown
- 2015-03-20 KR KR1020227029416A patent/KR20220123560A/ko active Pending
- 2015-03-20 RU RU2016141267A patent/RU2016141267A/ru not_active Application Discontinuation
- 2015-03-20 AU AU2015231001A patent/AU2015231001A1/en not_active Abandoned
- 2015-03-20 TW TW104109072A patent/TWI684600B/zh active
- 2015-03-20 CN CN201911110229.XA patent/CN110845615B/zh active Active
- 2015-03-20 TW TW108148404A patent/TWI731535B/zh active
- 2015-03-20 RU RU2020124944A patent/RU2020124944A/ru unknown
- 2015-03-20 TW TW110118262A patent/TW202214691A/zh unknown
- 2015-03-20 WO PCT/US2015/021849 patent/WO2015143382A1/en not_active Ceased
- 2015-03-20 JP JP2017501138A patent/JP2017511376A/ja not_active Ceased
- 2015-03-20 TW TW113122572A patent/TW202515912A/zh unknown
- 2015-03-20 EP EP22210013.3A patent/EP4218929A1/en active Pending
- 2015-03-20 CN CN201911110228.5A patent/CN110841074B/zh active Active
- 2015-03-20 CN CN201911110226.6A patent/CN111378041B/zh active Active
- 2015-03-20 SG SG11201607746QA patent/SG11201607746QA/en unknown
- 2015-03-20 SG SG10201908460Y patent/SG10201908460YA/en unknown
- 2015-03-20 KR KR1020167029392A patent/KR20160138177A/ko not_active Abandoned
- 2015-03-20 CR CR20160487A patent/CR20160487A/es unknown
- 2015-03-20 AR ARP150100849A patent/AR099812A1/es unknown
- 2015-03-20 TW TW111137074A patent/TW202330606A/zh unknown
- 2015-03-20 MX MX2016012207A patent/MX385853B/es unknown
- 2015-03-20 IL IL295906A patent/IL295906A/en unknown
- 2015-03-20 UA UAA201610588A patent/UA125575C2/uk unknown
- 2015-03-20 UY UY0001036041A patent/UY36041A/es not_active Application Discontinuation
- 2015-03-20 US US14/664,453 patent/US9493568B2/en active Active
- 2015-03-20 CN CN201580026453.4A patent/CN106459200B/zh active Active
- 2015-03-20 PE PE2016001657A patent/PE20161211A1/es unknown
-
2016
- 2016-09-19 PH PH12016501828A patent/PH12016501828A1/en unknown
- 2016-09-20 CL CL2016002359A patent/CL2016002359A1/es unknown
- 2016-09-20 DO DO2016000252A patent/DOP2016000252A/es unknown
- 2016-09-20 IL IL247936A patent/IL247936A0/en unknown
- 2016-09-20 MX MX2021010471A patent/MX2021010471A/es unknown
- 2016-10-19 EC ECIEPI201682556A patent/ECSP16082556A/es unknown
- 2016-11-11 US US15/349,692 patent/US9827330B2/en active Active
-
2017
- 2017-11-09 US US15/808,419 patent/US10098968B2/en active Active
-
2018
- 2018-04-18 CL CL2018001000A patent/CL2018001000A1/es unknown
- 2018-10-08 US US16/154,229 patent/US20190134216A1/en not_active Abandoned
-
2019
- 2019-11-25 JP JP2019212012A patent/JP2020039360A/ja not_active Ceased
-
2020
- 2020-02-07 US US16/785,015 patent/US20200405878A1/en not_active Abandoned
- 2020-10-09 AU AU2020250319A patent/AU2020250319A1/en not_active Abandoned
-
2021
- 2021-02-01 DO DO2021000023A patent/DOP2021000023A/es unknown
- 2021-02-23 CL CL2021000458A patent/CL2021000458A1/es unknown
- 2021-03-26 JP JP2021052772A patent/JP2021104030A/ja not_active Ceased
- 2021-04-05 AR ARP210100874A patent/AR121749A2/es unknown
- 2021-10-20 US US17/451,622 patent/US20220288221A1/en not_active Abandoned
-
2023
- 2023-02-22 JP JP2023025869A patent/JP2023062162A/ja not_active Ceased
- 2023-06-08 AU AU2023203573A patent/AU2023203573A1/en not_active Abandoned
-
2024
- 2024-05-02 JP JP2024074883A patent/JP2024102229A/ja not_active Ceased
- 2024-05-21 US US18/670,261 patent/US20250163159A1/en active Pending
-
2025
- 2025-05-29 AU AU2025204009A patent/AU2025204009A1/en active Pending
- 2025-07-02 JP JP2025112297A patent/JP2025143392A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017511376A5 (enExample) | ||
| WO2020114480A1 (en) | Anti-claudin antibodies and uses thereof | |
| JP6974311B2 (ja) | 新規ｐｄ−１免疫調節剤 | |
| DK2220121T3 (en) | AXL antibodies | |
| CN109310885B (zh) | NaPi2b靶向抗体-药物缀合物及其使用方法 | |
| JP6181089B2 (ja) | 条件依存活性抗上皮細胞増殖因子受容体抗体およびその使用方法 | |
| AU2008256644B2 (en) | Intranuclear protein transduction through a nucleoside salvage pathway | |
| JP2021104030A (ja) | 抗ｅｇｆｒ抗体及び抗体薬物コンジュゲート | |
| US20230287139A1 (en) | Anti-her2/pd1 bispecific antibody | |
| US20210100838A1 (en) | Human antibodies that bind and are internalized by mesothelioma and other cancer cells | |
| JP2016536342A (ja) | 修飾抗上皮成長因子受容体抗体およびその使用法 | |
| KR20140008308A (ko) | 신규한 egfr-결합 분자 및 이의 면역컨쥬게이트 | |
| JP2020527332A5 (enExample) | ||
| CN110204614A (zh) | 抗人lag-3单克隆抗体及其制备方法和用途 | |
| KR20220129030A (ko) | 항-Gal3 항체 및 사용 방법 | |
| JP2022534297A (ja) | 抗ｂ７－ｈ３抗体 | |
| TW200918556A (en) | Treatment of tumors using specific anti-L1 antibody | |
| JP2022550364A (ja) | 新規抗ｐｄ－ｌ１／抗ｌａｇ－３二重特異性抗体およびその使用 | |
| Wang et al. | Construction of a novel TROP2/CD3 bispecific antibody with potent antitumor activity and reduced induction of Th1 cytokines | |
| WO2024131835A1 (en) | Ligand-cytotoxicity drug conjugates and pharmaceutical uses thereof | |
| KR20250004821A (ko) | 항체-약물 접합체와 ezh1 및/또는 ezh2 억제제의 조합 | |
| TW202417054A (zh) | 配體－細胞毒性藥物偶聯物及其藥物用途 | |
| Junttila et al. | 515 POSTER Trastuzumab-mertansine (T-DM1) retains all the mechanisms of action (MOA) of trastuzumab and is extremely effective in combination with docetaxel | |
| Tolcher et al. | 514 POSTER A novel dosing strategy based on plasma levels of CanAg in a Phase II study of IMGN242 (HUC242-DM4) in gastric cancer | |
| HK1262681B (en) | Anti-lag-3 antibodies and uses thereof |